Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Andrew Technologies, LLC
TUSTIN, Calif., Oct. 9, 2013 /PRNewswire/ -- Andrew Technologies, LLC commences national launch of HydraSolve® with a Hot Topics presentation by Dr. Christopher Godek at American Society of Plastic Surgery (ASPS) meeting on Friday, October 11th during the 10:21am session. After successful completion of the HydraSolve® Expert Release program with select leading plastic surgeons, Andrew Technologies will launch the second production lot of this innovative system, thereby expanding the offering of gentle body contouring to larger numbers of potential patients.
During the ASPS meeting, Andrew Technologies will be at Booth 1926 in the exhibit hall to address plastic surgeon's questions about HydraSolve®. Dr. Mark S. Andrew, inventor of HydraSolve®, founder of Andrew Technologies and Chief Scientific Officer of the company, will also be available at the booth to review videos of recent cases and discuss clinical observations from his extensive experience with the technology. A special purchase offer on the HydraSolve® System will be made available exclusively during the meeting to the first 25 plastic surgeons who commit to clinical demonstrations at their practices.
In addition, plastic surgeon Dr. Steven R. Cohen will be conducting a live HydraSolve® procedure at his La Jolla office, where a limited number of interested U.S. plastic surgeons will be able to observe. To observe a HydraSolve® case on Saturday October 12th at Faces+, 4510 Executive Drive, San Diego, CA, please contact firstname.lastname@example.org.
HydraSolve® has emerged as one of the leading new aesthetic surgery technologies, as indicated by its selection as one of four technologies featured in the inaugural Aesthetic Surgery Education and Research Foundation (ASERF) Global Hot Topics "365" Webinar on October 1st. As Indiana plastic surgeon Bruce Van Natta, MD, commented, "I have found that HydraSolve® rapidly removes fat and produces a nearly bloodless fat layer of uniform particles that can be easily injected into breasts and other target tissues. It may be the best system I have used for autologous fat grafting. For large volumes, I wouldn't want to use anything else. There is nothing I am aware of that can remove large volumes of fat as safely and efficiently as HydraSolve®."
According to Tom Albright, CEO of Andrew Technologies, a 30-year industry veteran with commercial leadership experience, including Lipitor, BOTOX Cosmetic, and Latisse, "We are thrilled with the level of excitement about HydraSolve® from both consumers and plastic surgeons, especially given the early phase of our launch cycle."
HydraSolve® is a novel liposuction device based on the same patented Tissue Liquefaction Technology™ that was launched in 2003 by Alcon as the AquaLase® Liquefaction Device, a modality on the Infiniti Vision System, for precision cataract surgery. HydraSolve® combines natural saline solution with low levels of pressure and temperature, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve® cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue. It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while not liquefying or cutting blood vessels, nerves or connective tissue. HydraSolve® achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes. For more information, please refer to www.hydrasolve.com
About Andrew Technologies, LLC
Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients' lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology. Andrew Technologies is a venture capital funded company based in Orange County, CA and Haddonfield, NJ. Our primary investors are WFD Ventures http://www.wfdventures.com/ and NJTC Venture Fund http://www.njtcvc.com/.
©2012 PR Newswire. All Rights Reserved.